Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study-Reference-Cited by-同舟云学术

Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study

Published:2017-11-22 Issue:3 Volume:20 Page:491-500
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Senni Michele¹,McMurray John J.V.²,Wachter Rolf³,McIntyre Hugh F.⁴,Anand Inder S.⁵,Duino Vincenzo¹,Sarkar Arnab⁶,Shi Victor⁷,Charney Alan⁷

Affiliation:

1. Cardiology Division, Cardiovascular Department; Hospital Papa Giovanni XXIII; Bergamo Italy

2. British Heart Foundation Cardiovascular Research Centre; University of Glasgow; Glasgow UK

3. Clinic for Cardiology and Pneumology; University Medical Centre Göttingen; Göttingen Germany

4. Cardiology Department; Conquest Hospital; St Leonards on Sea UK

5. Veterans Medical Center Minneapolis; Minneapolis MN USA

6. Novartis Healthcare Ltd; Hyderabad India

7. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

Funder

Novartis Pharmaceuticals Corporation, USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC;Ponikowski;Eur J Heart Fail,2016

2. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America;Yancy;Circulation,2016

3. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

4. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure;Packer;Circulation,2015

5. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial;Vardeny;Eur J Heart Fail,2016

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Heart Failure According to Baseline Systolic Blood Pressure　― Results From a Subgroup Analysis of the PARALLEL-HF Study ―;Circulation Journal;2023-12-25

2. Efficacy and safety of sacubitril/valsartan after six months in patients with heart failure with reduced ejection fraction and asymptomatic hypotension;Journal of Geriatric Cardiology;2023-12

3. Does sacubitril/valsartan work in children with heart failure?—a pilot study;Frontiers in Cardiovascular Medicine;2023-11-29

4. Hypotension and optimization of heart failure therapy after a recent hospitalization for heart failure: When the going gets tough, the tough get going;International Journal of Cardiology;2023-10

5. Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan;Cardiology Plus;2023-06-26